e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:07/July-2024 Impact Factor- 7.868 www.irjmets.com

GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS: A COMPREHENSIVE REVIEW

Bheemappa Teli*1, Ravichandran*2, Dr. Kavitha PN*3

*1,2K R College Of Pharmacy, Bengaluru, Karnataka, India.

*3Assistant Professor, Department Of Pharmaceutics K R College Of Pharmacy, Bengaluru, India.

*Corresponding Author: Ravichandran

ABSTRACT

Gastroretentive drug delivery systems (GRDDS) are a novel and emerging area of pharmaceutical research that aims at enhancing oral medication administration through boosting drug residence time in the stomach. This review addresses the various GRDDS, including floating, mucoadhesive, swelling, high-density, and magnetic systems. Each system's mechanism, design concepts, and therapeutic applications are clarified in detail. The advantages of GRDDS, such as increased bioavailability, reduced dose frequency, and localized treatment of stomach problems, are balanced against the disadvantages, which include heterogeneity in gastric physiology and formulation complexity. The review also discusses current advances and future prospects in GRDDS, with a focus on breakthroughs such smart polymers, nanotechnology, and biomimetic techniques. This comprehensive study aims to highlight the potential of GRDDS to considerably improve therapeutic results for medications with narrow absorption windows or those that require targeted gastric distribution.

I. INTRODUCTION

Oral drug delivery is the most frequent and recommended form of giving pharmaceuticals, with multiple advantages including convenience of use, patient compliance, and cost-effectiveness. However, it raises considerable hurdles, especially for medications with unique absorption properties or those that target local diseases in the gastrointestinal (GI) tract. Conventional oral dose forms frequently have disadvantages, such as quick gastric emptying and variable absorption rates, which can result in poor therapeutic results and lower drug efficacy.



HUMAN GASTROINTESTINAL TRACT

1. Gastrointestinal Tract and Drug Absorption

The gastrointestinal tract is a complex and dynamic system that has a considerable impact on the pharmacokinetics of oral medicines. Drug absorption takes place predominantly in the stomach and small intestine, which have separate physiological circumstances.

Stomach: The stomach's principal tasks are food storage, digesting, and regulation of chyme discharge into the small intestine. The stomach's acidic environment (pH 1.5-3.5) can influence drug stability and solubility. Furthermore, gastric emptying time can vary significantly, impacting how long a medicine remains in the stomach for absorption.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:07/July-2024 Impact Factor- 7.868 www.irjmets.com

Small intestine: It is the primary location of nutrition absorption and medication uptake due to its huge surface area, abundant blood supply, and neutral to slightly alkaline pH. However, medications that are absorbed largely in the upper small intestine may have low bioavailability if the stomach is quickly emptying.

II. LIMITATIONS OF CONVENTIONAL ORAL DRUG DELIVERY SYSTEMS

Narrow Absorption Windows: Drugs that are largely absorbed in the stomach or upper section of the small intestine may not achieve adequate therapeutic levels if they transit too fast through these areas.

Poor Solubility in Intestinal Fluids: Some medications are more soluble in the acidic environment of the stomach, but lose solubility in the more neutral pH of the small intestine.

Degradation by Alkaline pH or Enzymes: Drugs that are unstable or susceptible to degradation in the small intestine's alkaline environment may benefit from extended gastric retention.

To address these issues, gastroretentive drug delivery systems (GRDDS) were created. GRDDS are intended to increase drug retention time in the stomach, allowing for a longer duration of absorption and potentially increasing bioavailability. By lingering in the stomach for an extended period of time, GRDDS can provide sustained and regulated medication release, resulting in better therapeutic effects.

Mechanisms of Gastroretentive Drug Delivery Systems:

GRDDS employ various mechanisms to maintain the drug formulation in the stomach for extended durations. The key mechanisms include:

A. **Floating Systems**: Designed to remain buoyant on the gastric contents, floating systems reduce the rate of gastric emptying. They are classified into:

Effervescent Systems: Utilize gas-generating agents like sodium bicarbonate and citric acid to produce carbon dioxide, which helps the dosage form float.

Non-Effervescent Systems: Rely on swellable polymers such as hydroxypropyl methylcellulose (HPMC) or polyethylene oxide (PEO) to maintain buoyancy.

B. **Mucoadhesive Systems**: These systems attach to the gastric mucosa with bioadhesive polymers such as chitosan or carbopol, extending gastric residency time despite the stomach's dynamic environment.

C. **High-Density Systems**: These systems are designed to be heavier than gastric fluids, so they sink to the stomach's bottom and resist peristaltic movements, delaying gastric emptying.

D. **Magnetic Systems**: These systems use magnetic materials and may be kept in the stomach with an external magnetic field, providing fine control over residence time and localization.

E. **Swelling and Expanding Systems**: When these systems come into contact with gastric fluids, they swell or expand to a size that prevents them from passing through the pylorus, allowing them to remain in the stomach longer. Polymers such as hydrogel are widely employed for their swelling characteristics.



e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:07/July-2024 Impact Factor- 7.868 www.irjmets.com

III. TYPES OF GASTRORETENTIVE DRUG DELIVERY SYSTEMS

GRDDS can be generically classified as single-unit and multiple-unit systems.

Single-Unit Systems: These are pills and capsules having floating or mucoadhesive qualities. Single-unit devices are simpler, but they have restrictions, such as the possibility of dose dumping or being evacuated while fasting.

Multiple-Unit Systems: These systems, which include pellets, microspheres, and mini-tablets, disperse more evenly in the stomach, lowering the risk of irregular gastric emptying and giving a more constant release profile.

IV. APPLICATIONS FOR GASTRORETENTIVE DRUG DELIVERY SYSTEMS

GRDDS are particularly useful for medications with site-specific absorption in the stomach or upper GI tract. Notable applications include:

Antibiotics: Drugs used to treat Helicobacter pylori infections, such as amoxicillin and tetracycline, benefit from prolonged stomach retention, which increases eradication rates.

Antacids and Antireflux Agents: GRDDS improve the efficacy of antacids and medications for gastroesophageal reflux disease (GERD) by sustaining therapeutic levels in the stomach for extended periods of time.

Antidiabetic medicines: GRDDS can maintain plasma levels and improve glycemic control for medicines with optimal upper GI tract absorption, such as metformin.

NSAIDs with Analgesics: Gastroretentive formulations can reduce the gastric irritation caused by nonsteroidal anti-inflammatory medications (NSAIDs) by allowing for regulated release within the stomach.

V. BENEFITS OF GASTRORETENTIVE DRUG DELIVERY SYSTEMS

Enhanced Bioavailability: By lengthening the stomach's residency period, GRDDS improves medication absorption in the upper GI tract.

Sustained medication: Results in lower dose frequencies, which improves patient adherence and convenience.

Targeted Therapy: GRDDS offer localized treatment for stomach-specific disorders, limiting systemic exposure and potential side effects.

Improved Therapeutic Outcomes: Controlled medication release and increased absorption help to improve overall therapeutic efficacy.

VI. CHALLENGES IN GASTRORETENTIVE DRUG DELIVERY SYSTEMS

Regardless of their promise, GRDDS have various challenges:

Variability in stomach Physiology: Individual differences in stomach emptying rates, pH levels, and motility can all have an impact on GRDDS performance and consistency.

Food Effects: The presence of food in the stomach can drastically change the retention time and medication release characteristics of GRDDS.

Sophisticated Formulation Requirements: Developing stable and reproducible GRDDS requires sophisticated formulation techniques and manufacturing procedures, which may increase development costs and time.

VII. FUTURE DIRECTIONS AND INNOVATION

The future of gastroretentive medication delivery seems optimistic, with ongoing research and technical breakthroughs opening the way for creative solutions.

Smart Polymers: Polymers that respond to environmental cues such as pH, temperature, or enzymatic activity can deliver more precise and targeted medication release.

Nanotechnology: Nanoparticles and nano formulations provide greater control over drug release and improve mucoadhesive qualities, potentially increasing the efficacy of GRDDS.

Biomimetic Approaches: Using natural systems and biological mechanisms can result in more efficient, biocompatible, and patient-friendly GRDDS.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:07/July-2024 Impact Factor- 7.868 www.irjmets.com

VIII. CONCLUSION

Gastroretentive drug delivery devices represent a significant development in oral medication administration, particularly for medicines with low upper GI absorption. While there are obstacles to overcome, integrating novel materials and technologies has the potential to significantly increase GRDDS's capabilities and uses. Future improvements in this discipline are likely to improve therapeutic outcomes and open up new avenues for focused and efficient medication delivery.

IX. REFERENCES

[1] Streubel, A., Siepmann, J., &Bodmeier, R. (2006). Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 3(2), 217-233.

[2] Mojaverian, P., Ferguson, R. K., Vlasses, P. H., Rocci, M. L., Jr, Oren, A., Fix, J. A., Caldwell, L. J., & Gardner, C. R. (1985). Estimation of gastric residence time of the Heidelberg cpsule in humans: effect of varying food composition. Gastroenterology, 89(2), 392-397.

[3] Rouge, N., Buri, P., & Doelker, E. (1996). Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 136(1-2), 117-139.

[4] Harikumar, S. L., Sharma, R., & Nirmala, R. (2012). Gastro-retentive drug delivery systems: a review. International Journal of Drug Development and Research, 4(4), 28-39.

[5] Chavanpatil, M., Jain, P., Chaudhari, S., Shear, R., &Vavia, P. (2006). Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. International Journal of Pharmaceutics, 316(1-2), 86-92.

[6] Badoni A, Ojha A, Gnanarajan G, Kothiyal P. Review on gastroretentive drug delivery system. J Pharm Innov. 2012;1:32–42.

[7] Kumar M, Kaushik D. An Overview on various approaches and recent patents on gastroretentive drug delivery systems. Recent Pat Drug Deliv Formul. 2018;12:84–92.

[8] Gunda RK. Formulation development and evaluation of gastroretentive drug delivery system. A review. J Pharm Res. 2017;8:11–20.

[9] Devkant S, Anjali S. Gastro retentive drug delivery system. A review. Asian Pac J Health Sci. 2014;1:80–89.

[10] Tomar A, Upadhyay A, Gupta S, Kumar S. An overview on gastroretentive drug delivery system: current approaches and advancements. Res Pharm Sci. 2019; 9: 12–16.